Endocan overexpression at either messenger ribonucleic acid (mRNA) or protein level have been observed in pituitary adenoma (9, 10), gastric cancer (11), bladder cancer (12), non-small cell lung cancer (13), colorectal cancer (14), glioblastoma (15), renal cell carcinoma (16), hepatocellular carcinoma (17), squam-ous cell carcinoma of head and neck (18, 19), pancreatic neuroendocrine tumor (20) and ovarian cancer (21). Here, ESM1 is linked to ovarian carcinoma.